Statement: the primary trial and the secondary trial report their results as perecentages but use different units of measure. folh1 antibody is any immunoglobulin that recognizes glutamate carboxypeptidase 2 (folate hydrolase 1).
Primary_evidence: Outcome Measurement:    Objective Response Rate   The objective response rate (ORR) was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.   Time frame: Evaluated every 6 weeks from the time of their first treatment, per RECIST 1.1. Duration of therapy will depend on individual response, evidence of disease progression and tolerance, up to 1 year Results 1:    Arm/Group Title: Cisplatin + AZD1775   Arm/Group Description: Treatment will consist of one cycle of cisplatin monotherapy (cisplatin 75 mg/m2 IV x1) followed by combination therapy of AZD1775 plus cisplatin starting 21 days(1 cycle) later.   AZD1775 will be administered 200 mg as twice daily oral dosing predetermined dosing schedule, in combination with Cisplatin predetermined dosage every 21 days.   At least 10 patients will undergo a research biopsy within 5-48 hours after beginning cisplatin (Cycle 1 Day 1) and then again within 5-8 hours after the last dose of AZD1775 in cycle 2 (Cycle 2 Day 3).   Overall Number of Participants Analyzed: 34   Measure Type: Number   Unit of Measure: percentage of participants  26        (13 to 44)
Secondary_evidence: Outcome Measurement:    Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods   Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval.   Time frame: Baseline Results 1:    Arm/Group Title: Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)   Arm/Group Description: Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.   Overall Number of Participants Analyzed: 92   Measure Type: Number   Unit of Measure: proportion of nodes  Proportion of SNs (PTc) detected by Tc method: 0.86   Proportion of SNs (PICG) detected by ICG method: 0.95